Showing 551-560 of 1321 results for "".
- Gentle Cleansers Kill Viruses as Effectively as Harsh Soapshttps://practicaldermatology.com/news/gentle-cleansers-kill-viruses-as-effectively-as-harsh-soaps/2461780/Gentle cleansers are just as effective in killing viruses – including coronavirus - as harsh soaps, a new study out University of Sheffield experts has found. Scientists from the University of Sheffield’s Sh
- And the Winners Are…Botox Cosmetic Announces the Winners of the IFundWomen Grant Programhttps://practicaldermatology.com/news/and-the-winners-arebotox-cosmetic-announces-the-winners-of-the-ifundwomen-grant-program/2461779/Twenty female entrepreneurs will receive funding and mentorship through Allergan’s BOTOX Cosmetic and IFundWomen grant program. "There were so many remarkable applications that featured thoughtful business solutions," says Carrie Strom, President, Global Aller
- Fall Clinical PAs & NP Update: Castle's DecisionDx-SCC Can Identify Tumors Likely to Spread in Low-Risk CSCChttps://practicaldermatology.com/news/fall-clinical-pas-np-update/2461778/Castle Biosciences, Inc.’s DecisionDx-SCC test can identify tumors likely to metastasize in patients with cutaneous squamous cell carcinoma deemed low risk by traditional staging, according to research presented at the the 2023 Fall Clinical Dermatology Conference for PAs &am
- Highly Trafficked Roads Up AD Risk in Kids, Teenshttps://practicaldermatology.com/news/highly-trafficked-roads-up-ad-risk-in-kids-teens/2461772/Traffic-related air pollution may increase children and teen’s risk for atopic dermatitis report researchers at National Jewish Health in Denver, Colo. For the study, researchers reviewed charts of patients 0-18 years of age who had been seen at National Jewish Health i
- Biosimilar Update: Dr. Reddy’s Completes Phase I Study of Proposed Tocilizumab Biosimilarhttps://practicaldermatology.com/news/biosimilar-update-dr-reddys-completes-phase-i-study-of-proposed-tocilizumab-biosimilar/2461765/Dr. Reddy’s Laboratories’ tocilizumab biosimilar candidate, DRL_TC, met its primary and secondary endpoints in a Phase I study. The company is now initiating a global Phase III study with the aim of comparing the efficacy, safety, tolerability and immunogeni
- Sol-Gel, Searchlight Pharma Partner to Commercialize TWYNEO and EPSOLAY in Canadahttps://practicaldermatology.com/news/sol-gel-searchlight-pharma-partner-to-commercialize-twyneo-and-epsolay-in-canada/2461764/Israel’s Sol-Gel Technologies, Ltd. and Searchlight Pharma Inc. have signed exclusive license agreements for TWYNEO and EPSOLAY for the Canadian market. Both products recently launched in the U.S., and Searchlight is to commercialize in Canada over a fifteen-year term that i
- Can Softening Stem Cells Coax Hair Growth in Aging Hair? Maybehttps://practicaldermatology.com/news/can-softening-stem-cells-coax-hair-growth-in-aging-hair/2461761/Hair follicle stem cells get stiff with age, making it harder for them to grow hair, but if the hair follicle’s stem cells are softened, they are more likely to produce hair, new research suggests. In a study in mice
- Sun Pharma’s Ilumetri (Tildrakizumab Injection) Scores Nod For Plaque Psoriasis in Chinahttps://practicaldermatology.com/news/sun-pharmas-ilumetri-tildrakizumab-injection-scores-nod-for-plaque-psoriasis-in-china/2461753/The New Drug Application (NDA) of tildrakizumab injection under the brand name of Ilumetri has been approved by the National Medical Products Administration of the People’s Republic of China, Sun Pharma reports. Ilumetri is indicated for the treatment of adults wit
- Sun Pharma, Philogen Enter Into an Exclusive Distribution, License, and Supply Agreement for Nidlegy in Europe, Australia, and New Zealandhttps://practicaldermatology.com/news/sun-pharma-philogen-enter-into-an-exclusive-distribution-license-and-supply-agreement-for-nidlegy-in-europe-australia-and-new-zealand/2461752/Sun Pharmaceutical Industries has entered into a licensing agreement for commercializing Philogen’s Nidlegy (Daromun) in the territories of Europe, Australia and New Zealand. Nidlegy, currently in Phase III clinical trials, is a new anti-cancer biopharmaceutical which is bei
- Nivea's Skin Out Loud Series Tackles Skin Diversityhttps://practicaldermatology.com/news/niveas-skin-out-loud-series-tackles-skin-diversity/2461751/Nivea is rolling out a five-episode "Skin Out Loud" series. The series features a diverse cast of hosts including TV Host Milka Loff Fernandes, Brigiding from RuPaul's Drag Race Philippines, South African skinfluencer Zithobe